Download
s00204-021-03174-1.pdf 7,17MB
WeightNameValue
1000 Titel
  • Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3
1000 Autor/in
  1. Wachholz, Vanessa |
  2. Mustafa, Al-Hassan M. |
  3. Zeyn, Yanira |
  4. Henninger, Sven J. |
  5. Beyer, Mandy |
  6. Dzulko, Melanie |
  7. Piée-Staffa, Andrea |
  8. Brachetti, Christina |
  9. Haehnel, Patricia S. |
  10. Sellmer, Andreas |
  11. Mahboobi, Siavosh |
  12. Kindler, Thomas |
  13. Brenner, Walburgis |
  14. Nikolova, Teodora |
  15. Krämer, Oliver |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-10-19
1000 Erschienen in
1000 Quellenangabe
  • 96(1):177-193
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00204-021-03174-1 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748367/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase (FLT3) is a clinically unresolved problem. AML cells frequently have a dysregulated expression and activity of epigenetic modulators of the histone deacetylase (HDAC) family. Therefore, we tested whether a combined inhibition of mutant FLT3 and class I HDACs is effective against AML cells. Low nanomolar doses of the FLT3 inhibitor (FLT3i) AC220 and an inhibition of class I HDACs with nanomolar concentrations of FK228 or micromolar doses of the HDAC3 specific agent RGFP966 synergistically induce apoptosis of AML cells that carry hyperactive FLT3 with an internal tandem duplication (FLT3-ITD). This does not occur in leukemic cells with wild-type FLT3 and without FLT3, suggesting a preferential toxicity of this combination against cells with mutant FLT3. Moreover, nanomolar doses of the new FLT3i marbotinib combine favorably with FK228 against leukemic cells with FLT3-ITD. The combinatorial treatments potentiated their suppressive effects on the tyrosine phosphorylation and stability of FLT3-ITD and its downstream signaling to the kinases ERK1/ERK2 and the inducible transcription factor STAT5. The beneficial pro-apoptotic effects of FLT3i and HDACi against leukemic cells with mutant FLT3 are associated with dose- and drug-dependent alterations of cell cycle distribution and DNA damage. This is linked to a modulation of the tumor-suppressive transcription factor p53 and its target cyclin-dependent kinase inhibitor p21. While HDACi induce p21, AC220 suppresses the expression of p53 and p21. Furthermore, we show that both FLT3-ITD and class I HDAC activity promote the expression of the checkpoint kinases CHK1 and WEE1, thymidylate synthase, and the DNA repair protein RAD51 in leukemic cells. A genetic depletion of HDAC3 attenuates the expression of such proteins. Thus, class I HDACs and hyperactive FLT3 appear to be valid targets in AML cells with mutant FLT3.
1000 Sacherschließung
lokal Cyclin-Dependent Kinase Inhibitor p21/metabolism [MeSH]
lokal Drug interaction
lokal Protein Kinase Inhibitors/pharmacology [MeSH]
lokal Molecular Toxicology
lokal Humans [MeSH]
lokal FLT3-ITD
lokal Apoptosis [MeSH]
lokal HDAC
lokal TKi
lokal Leukemia, Myeloid, Acute/genetics [MeSH]
lokal fms-Like Tyrosine Kinase 3/metabolism [MeSH]
lokal fms-Like Tyrosine Kinase 3/genetics [MeSH]
lokal Leukemia, Myeloid, Acute/drug therapy [MeSH]
lokal HDACi
lokal AML
lokal Histone Deacetylases/metabolism [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/V2FjaGhvbHosIFZhbmVzc2E=|https://orcid.org/0000-0002-4453-2573|https://frl.publisso.de/adhoc/uri/WmV5biwgWWFuaXJh|https://frl.publisso.de/adhoc/uri/SGVubmluZ2VyLCBTdmVuIEou|https://frl.publisso.de/adhoc/uri/QmV5ZXIsIE1hbmR5|https://frl.publisso.de/adhoc/uri/RHp1bGtvLCBNZWxhbmll|https://frl.publisso.de/adhoc/uri/UGnDqWUtU3RhZmZhLCBBbmRyZWE=|https://frl.publisso.de/adhoc/uri/QnJhY2hldHRpLCBDaHJpc3RpbmE=|https://frl.publisso.de/adhoc/uri/SGFlaG5lbCwgUGF0cmljaWEgUy4=|https://frl.publisso.de/adhoc/uri/U2VsbG1lciwgQW5kcmVhcw==|https://frl.publisso.de/adhoc/uri/TWFoYm9vYmksIFNpYXZvc2g=|https://frl.publisso.de/adhoc/uri/S2luZGxlciwgVGhvbWFz|https://orcid.org/0000-0002-1511-6212|https://frl.publisso.de/adhoc/uri/Tmlrb2xvdmEsIFRlb2RvcmE=|https://orcid.org/0000-0003-3973-045X
1000 Hinweis
  • DeepGreen-ID: 4d5e82ab75c74334913129b88afd01fc ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6451629.rdf
1000 Erstellt am 2023-05-11T14:13:52.131+0200
1000 Erstellt von 322
1000 beschreibt frl:6451629
1000 Zuletzt bearbeitet Tue Oct 24 07:41:26 CEST 2023
1000 Objekt bearb. Tue Oct 24 07:41:26 CEST 2023
1000 Vgl. frl:6451629
1000 Oai Id
  1. oai:frl.publisso.de:frl:6451629 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source